Acute Health Effects of Traffic-Related Air Pollution Exposure

Sponsor
Fudan University (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04153539
Collaborator
(none)
69
1
2
38.7
1.8

Study Details

Study Description

Brief Summary

This study aims to assess the effects of acute exposure to traffic-related air pollution and the underlying mechanisms.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Walking along a busy road
  • Behavioral: Walking in a traffic-free park
N/A

Detailed Description

The investigators will conduct a randomized, crossover trial among 72 healthy young adults in Shanghai, China. The eligible participants will be randomly divided into 2 groups (36 volunteers per group). During the first stage, participants will be requested to take one walking task (from 13:00 to 17:30). The exposed group will walk along a busy road and be exposed to traffic-related air pollution, while the control group will walk in a traffic-free park. During the first 3 hours, all participants will rest for 30 minutes after each 15-minute walking. From 16:00, participants will stop walking and rest for 1.5 hours. Then both groups will enter a 2-week washout period. In the second stage, there will also be one walking task (from 13:00 to 17:30). The two groups will exchange their walking sites and repeat the previous trial. Physical examinations will be performed both before and after each walking task. Besides, we will ask volunteers to stay in school during the two days before walking. Health examinations include symptoms questionnaires, blood pressure tests, Holter monitoring, and spirometry. We plan to collect blood, urine, oropharyngeal swabs, and exhaled breath condensate before exposure, about one hour after exposure, and next morning.

Study Design

Study Type:
Interventional
Actual Enrollment :
69 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Acute Health Effects of Traffic-Related Air Pollution Exposure Among Healthy Young Adults: A Randomized, Crossover Trial
Actual Study Start Date :
Oct 9, 2019
Actual Primary Completion Date :
Dec 8, 2019
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Walking along a busy road

Participants in this group will be asked to walk along a busy road for 4.5 hours.

Behavioral: Walking along a busy road
The intervention group will walk along a busy road and be exposed to traffic-related air pollution for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.

Active Comparator: Walking in a traffic-free park

Participants in this group will be asked to walk in a traffic-free park for 4.5 hours.

Behavioral: Walking in a traffic-free park
The control group will walk in a traffic-free park for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.

Outcome Measures

Primary Outcome Measures

  1. Changes in FEV1 [FEV1 will be examined before exposure, half an hour after exposure and 12 hours after exposure.]

    We plan to measure changes in forced expiratory volume in 1 second.

  2. Blood Pressure [Blood pressure will be measured for 24 hours from 8:00 am on the morning of intervention to 8:00 am on the next morning.]

    We plan to measure systolic blood pressure (SBP) and diastolic blood pressure (DBP).

  3. Heart Rate Variability Parameters [Volunteers will be asked to wear electrographic Holter monitors for 24 hours from 8:00 am on the morning of intervention to 8:00 am on the next morning.]

    We plan to measure heart rate variability (HRV) parameters.

Secondary Outcome Measures

  1. Changes of FVC [7:00 AM on the day of the walking session, half an hour after exposure and 12 hours after exposure (next morning)]

    Changes of forced vital capacity

  2. Changes of FEV1/FVC [7:00 AM on the day of the walking session, half an hour after exposure and 12 hours after exposure (next morning)]

    Changes of the ratio of forced expired volume in 1 second (FEV1) to forced vital capacity (FVC)

  3. Changes of MMEF [7:00 AM on the day of the walking session, half an hour after exposure and 12 hours after exposure (next morning)]

    Changes of maximal mid-expiratory flow

Other Outcome Measures

  1. Differences in DNA methylation levels detected in whole-blood between the two exposures [1 hour after the end of the exposure session]

    Genome-wide DNA methylation in whole-blood were detected using Illumina 850K Beadchip. The study is to identify differential CpG loci after TRAP exposure

  2. Differences in exosome RNA expression levels detected in plasma transcriptomics between the two exposures [1 hour after the end of the exposure session]

    Illumina-based transcriptomics is non-targeted. The study is to find the differentially expressed exosome RNA in plasma after TRAP exposure

  3. Differences in exosome miRNA expression levels detected in plasma transcriptomics between the two exposures [1 hour after the end of the exposure session]

    Illumina-based transcriptomics is non-targeted. The study is to find the differentially expressed exosome miRNA in plasma after TRAP exposure

  4. Differences in protein levels detected in plasma proteomics between the two exposures [1 hour after the end of the exposure session]

    Mass spectrometry-based plasma proteomics is non-targeted. The study is to find the differentially expressed proteins in plasma after TRAP exposure

  5. Differences in metabolic profiling detected in serum mass spectrometry-based non-targeted metabolomics between the two exposures [1 hour after the end of the exposure session]

    The study is to explore the differential metabolic profiling in serum after TRAP exposure.

  6. Differences in metabolic profiling detected in urine mass spectrometry-based non-targeted metabolomics between the two exposures [1 hour after the end of the exposure session]

    The study is to explore the differential metabolic profiling in urine after TRAP exposure.

  7. Differences in lipids levels detected in serum lipidomics between the two exposures [1 hour after the end of the exposure session]

    Mass spectrometry-based serum lipids is non-targeted. The study is to find the differential lipids in serum between the road scenario and the park scenario

  8. Differences in protein levels detected in targeted serum proteomic chip between the two exposures [1 hour after the end of the exposure session]

    Targeted serum proteomic chip was conducted using the RayBio Biotin Label-based Human Antibody Array, which covers a total of 507 human proteins, including cytokines, inflammatory proteins, growth factors, cell adhesion molecules, soluble receptors and chemokines, and proteins related to angiogenesis and atherosclerosis. The study is to find the differential proteins in serum between the road scenario and the park scenario

  9. Differences in metabolic profiling detected in airway mass spectrometry-based non-targeted metabolomics between the two exposures [1 hour after the end of the exposure session]

    The study is to explore the differential metabolic profiling in exhaled breath condensate after TRAP exposure.

  10. Change in CRP concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of C-reactive protein

  11. Change in ITAC concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Interferon-induced T-cell alpha chemoattractant

  12. Change in GM-CSF concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Granulocyte-macrophage colony-stimulating factor

  13. Change in IFN-gamma concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Interferon-gamma

  14. Change in IL-10 concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Interlukin-10

  15. Change in IL-17A concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Interleukin-17A

  16. Change in IL-1 beta concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Interlukin-1 beta

  17. Change in IL-23 concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Interleukin-23

  18. Change in IL-6 concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Interleukin-6

  19. Change in IL-8 concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Interleukin-8

  20. Change in TNF alpha concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Tumor necrosis factor-α

  21. Change in MDA concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Malondialdehyde

  22. Change in 8-OH-DG concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the urine concentrations of 8-hydroxy-2'-deoxyguanosine

  23. Change in ACE concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session]

    Change in the serum concentrations of Angiotensin converting enzymes

  24. Change in Angiotensin II concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session]

    Change in the serum concentrations of Angiotensin II

  25. Change in ALD concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session]

    Change in the urine concentrations of Aldosterone

  26. Change in TF concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session]

    Change in the serum concentrations of Tissue factor

  27. Change in Fibrinogen concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session]

    Change in the serum concentrations of Fibrinogen

  28. Change in PAI-1 concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session]

    Change in the serum concentrations of Plasminogen Activator inhibitor-1

  29. Change in vWF concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session]

    Change in the serum concentrations of von Willebrand factor

  30. Change in CRF concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Corticotropin-Releasing Factor

  31. Change in ACTH concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Adrenocorticotropic hormone

  32. Change in Cortisol concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Cortisol

  33. Change in Cholesterol concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Cholesterol

  34. Change in TAG concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Triglyceride

  35. Change in LDL-C concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Low-density lipoprotein cholesterol

  36. Change in Glucose concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Glucose

  37. Change in Insulin concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning]

    Change in the serum concentrations of Insulin

  38. Changes in SP-D concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session]

    Change in the serum concentrations of surfactant proteins D

  39. Changes in Ezrin concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session]

    Change in the exhaled breath condensate concentrations of Ezrin

  40. Changes in 8-isoprostane concentrations between the two exposures [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session]

    Change in the exhaled breath condensate concentrations of 8-isoprostane

  41. Changes in TNF-α concentrations [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session]

    Change in the exhaled breath condensate concentrations of tumor necrosis factor-α

  42. Changes of the scores of respiratory symptoms questionnaires [7:00 AM on the day of the walking session, 1 hour after the end of the exposure session]

    Changes of scores of respiratory symptoms questionnaires both the total and each symptom specified

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 30 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Living in Shanghai during the study period;

  • Body mass index > 18.5 and ≤ 28;

  • Non-smoking, no history of alcohol or drug abuse;

  • Completing the walking task we required.

Exclusion Criteria:
  • Current or ever smokers;

  • Subjects with allergic disease, such as allergic rhinitis, allergic asthma, and atopy;

  • Subjects with cardiovascular disease, such as congenital heart disease, pulmonary heart disease, and hypertension;

  • Subjects with respiratory disease, such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease;

  • Subjects wih chronic disease, such as diabetes, chronic hepatitis, and kidney disease;

  • Subjects with a history of major surgery;

  • Abnormal spirometry (FEV1 and FVC ≤ 75% of predicted and FEV1/FVC ≤ 0.65);

  • Medication use or dietary supplements intake in recent two months;

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Environmental Health, School of Public Health, Fudan University Shanghai Shanghai China 200032

Sponsors and Collaborators

  • Fudan University

Investigators

  • Study Director: Haidong Kan, PhD, Department of Environmental Health, School of Public Health, Fudan University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Haidong Kan, Professor, Fudan University
ClinicalTrials.gov Identifier:
NCT04153539
Other Study ID Numbers:
  • FDUEH-6
First Posted:
Nov 6, 2019
Last Update Posted:
Mar 16, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Haidong Kan, Professor, Fudan University

Study Results

No Results Posted as of Mar 16, 2022